Logo

AEMD

Aethlon Medical, Inc.

AEMD

Aethlon Medical, Inc. • NASDAQ
$4.47 ▲ 4.93% (+0.21)
Market Cap $11.62 M
52w High $84.80
52w Low $3.42
Dividend Yield 0%
P/E 0.02
Volume 8.94K
Outstanding Shares 2.60M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2026 $0 $1.357M ▼ $-1.487M ▲ 0% $-3.74 ▲ $-1.334M ▲
Q1-2026 $0 $1.637M ▼ $-1.762M ▲ 0% $-8.5 ▲ $-1.607M ▲
Q4-2025 $0 $1.92M ▲ $-6.255M ▼ 0% $-40.1 ▼ $-6.161M ▼
Q3-2025 $0 $1.815M ▼ $-1.755M ▲ 0% $-8.6 ▲ $-1.731M ▲
Q2-2025 $0 $2.902M $-2.807M 0% $-13.8 $-2.816M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2026 $5.853B ▲ $7.323B ▲ $1.577B ▲ $5.746B ▲
Q1-2026 $3.765M ▼ $5.306M ▼ $1.882M ▼ $3.424M ▼
Q4-2025 $5.501M ▲ $7.36M ▲ $2.236M ▲ $5.124M ▲
Q3-2025 $4.825M ▼ $6.525M ▼ $2.191M ▼ $4.334M ▼
Q2-2025 $6.859M $8.847M $2.828M $6.019M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2026 $-1.487M ▲ $-1.659M ▲ $0 $3.741M ▲ $2.088M ▲ $-1.659M ▲
Q1-2026 $-1.762B ▼ $-1.715B ▼ $0 ▼ $-5.357M ▼ $-1.736B ▼ $-1.715B ▼
Q4-2025 $-6.255M ▼ $-1.673M ▲ $2.192K ▲ $2.359M ▲ $686.181K ▲ $-1.67M ▲
Q3-2025 $-1.755M ▲ $-2.011M ▲ $-2.192K ▼ $-7.073K ▼ $-2.034M ▲ $-2.013M ▲
Q2-2025 $-2.807M $-2.215M $0 $-3.832K $-2.213M $-2.215M

Revenue by Products

Product Q1-2022Q2-2022Q3-2022Q4-2022
Aethlon
Aethlon
 $0 ▲$0 ▲$0 ▲$0 ▲
E S I
E S I
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Aethlon Medical is essentially a pre-revenue company. Over the past several years it has not generated meaningful product or service sales, so its income statement is driven almost entirely by research, development, and overhead costs. Losses have been steady and modest in absolute dollar terms, but the per‑share loss looks very large because of repeated reverse stock splits and a small equity base, not because cash losses suddenly spiked. In practical terms, this is still an early-stage clinical company spending money to develop and test its technology rather than a business built around ongoing sales.

Balance Sheet

Balance Sheet The balance sheet is very small, with total assets made up largely of cash and no reported debt. That is a positive from a leverage standpoint, but the overall resource base is thin, leaving limited cushion to fund long development timelines without raising more capital. Equity is positive but modest, and the repeated reverse splits suggest that the company has likely issued shares over time to support operations. Overall, the balance sheet looks clean but fragile, typical of a micro-cap, clinical‑stage device developer with no commercial revenue yet.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, reflecting ongoing spending on R&D, clinical activities, and corporate overhead without offsetting revenue. Capital spending is minimal, so free cash flow is effectively the same as operating cash burn. This pattern indicates that the business depends on external financing—mainly equity—to keep funding trials and development. The cash burn does not appear extreme in size, but with a small cash balance it makes the timing and availability of future capital raises an important risk factor.

Competitive Edge

Competitive Edge Aethlon operates in a narrow but potentially important niche at the intersection of oncology and infectious disease, centered on its Hemopurifier device. It benefits from being an early mover in exosome and virus removal from blood, backed by patents and FDA Breakthrough Device designations, which together create meaningful barriers for direct copycats. However, its position is still more scientific than commercial: it has no established market share, and it competes indirectly with large, well‑funded companies in cancer, infectious disease, and extracorporeal therapies. Until clinical data and regulatory approvals are further advanced, its competitive strength remains more about future promise than present market power.

Innovation and R&D

Innovation and R&D Innovation is the core of Aethlon’s story. The Hemopurifier is designed as a broad‑spectrum filter for harmful exosomes and enveloped viruses, with potential use across multiple cancers, serious viral infections, and even areas like Long COVID and organ transplantation. The technology has scientific backing and regulatory recognition, and the company is running clinical trials in oncology while exploring collaborations in infectious disease and post‑viral conditions. That said, everything hinges on clinical and regulatory outcomes: until trials show clear, repeatable patient benefit and safety, the technology remains high‑potential but unproven, and timelines and ultimate applications carry significant uncertainty.

Summary

Aethlon Medical is a very early-stage, high‑risk, high‑uncertainty medical device company built around a single, novel platform rather than a diversified product portfolio. Financially, it has no revenue, ongoing losses, a small but debt‑free balance sheet, and relies on external capital to fund its work. Strategically, it holds distinctive technology and intellectual property in an area with real unmet medical needs, supported by favorable regulatory designations and exploratory clinical programs in several disease settings. The key questions going forward are whether the Hemopurifier can demonstrate strong clinical results, secure approvals, and attract partners or funding at scale before financial resources become too strained. Until those milestones are clearer, the story is driven more by development progress than by traditional financial performance.

NEWS

November 12, 2025 · 4:15 PM UTC

Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

Read more

November 7, 2025 · 8:01 AM UTC

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025

Read more

October 7, 2025 · 8:01 AM UTC

Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial

Read more

September 4, 2025 · 9:15 AM UTC

Aethlon Medical Announces Pricing of $4.5 Million Public Offering

Read more